

CORONA Remedies acquires Wokadine® from Dr. Reddy's

30 March 2026 | News

Increases equity among Surgeons, ENT, General Physicians & Gynaecologists



CORONA Remedies has announced the acquisition of Wokadine® from Dr. Reddy's Laboratories, a global pharmaceutical company headquartered in Hyderabad.

Effective March 30, 2026, the acquisition of Wokadine®, ranked #2 in the Povidone Iodine India market, reinforces CORONA's commitment to 'Healing' as the journey towards holistic recovery and health. This strategic acquisition enables CORONA Remedies to penetrate deeper into targeted specialty and offer wider accessibility. This brand holds strong potential for accelerated growth under CORONA Remedies' stewardship.

Integrating Wokadine® into its portfolio marks CORONA Remedies' entry into the Rs 648 crore Povidone Iodine market.

CORONA Remedies' sales & marketing team along with extensive distribution network will work to ensure that this newly acquired portfolio reaches patients across metro, semi-metro, urban, semi-urban and rural areas.

Wokadine® comprises of 14 SKUs having different applications, helping clinicians treat the ailing community. This acquisition will be fully funded through Company's internal accruals and cash.

Wokadine is an antiseptic and disinfectant agent. It is used in the treatment and prevention of infection in minor wounds, cuts, small burns, abrasions, and other infected skin conditions.

Commenting on the acquisition, Tejas Kothari, Vice President – Corporate Strategy & Business Development said, "We believe this acquisition will enhance and strengthen our existing product portfolio. By building on our strong relationships with healthcare professionals, we aim to deepen market penetration and are confident in accelerating the growth of this brand."